DOCSLIB.ORG

Outcome & Outlook

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Outcome & Outlook Newsletter No. 11 July 2019 — National Center of Competence in Research, RNA & Disease Message from the director’s desk Phase 2 Contract Signed: Outcome & Outlook Oliver Mühlemann, Director NCCR RNA & Disease It is now almost 2 years ago when I could internationally renowned expert in genome other requesting a succinct plan on how to announce in “The Messenger” the decision editing. His profile and research interests convert a research finding into a product or a of the Swiss National Science Foundation match perfectly with our NCCR’s mission and concrete medical application. The application (SNSF) to grant a second 4-year phase for we are looking forward for fruitful collabora- deadline for both calls has meanwhile past our NCCR. Meanwhile, namely on May 1st tions with his team in the future. and the evaluation of the proposals has been 2018, this second funding phase has started While our various research projects are initiated. I am very curious to find out who in and the transition was so smooth that most making steady progress and the past year has our network will be able to develop the most of our members probably barely noticed it. seen many first publications originating from promising translational research projects. The management and the steering commit- collaborative research initiated among differ- Last but not least, a group of people led tee, however, were a bit nervous to start this ent NCCR member groups, a description of by our communication delegate David Gat- second funding phase without knowing what these projects here would go beyond the field and the scientific officers has worked the exact budget for the coming four years scope of this brief summary about the state intensively, but thus far mostly behind the will be. The feeling was like being in the of the network. Nevertheless, I want to reit- scene, to substantially boost and profession- middle of building a house – having to de- erate that I judge these collaborations to be alize our communication activities. The har- cide on many details regarding bath, kitchen the most important achievement and biggest vest of all these preparative efforts has yet to and roof – without yet knowing how much added-value of the NCCR RNA & Disease. come, but we can already look forward to the mortgage the bank is going to give you. The In terms of our networking activities, the soon launch of a new webpage addressed to decision on the funding level was dependent undisputed recent highlight was the joint the lay public with the main goal of getting on the SNSF’s comparative evaluation of all 8 retreat between our NCCR and the Vienna kids and young adults interested in life sci- NCCRs of the 4th series, which was finished RNA community near Salzburg in February ence. Ideas for entertaining and educational only in December 2018. (see page 5 in this Newsletter), and the next content for this website are highly welcome Our nervousness turned into relief and highlight is just around the corner: in Au- and should be forwarded to David, Larissa happiness, when just before Christmas we gust, the third NCCR RNA & Disease Sum- and Dominik. were informed that the NCCR RNA & Disease mer School “RNA Regulation in Health and was one of the three top-ranked NCCRs that Disease” will take place in Saas-Fee and the That’s all for now, enjoy reading this issue would receive a 7.5% increase in the SNSF organisers (Constance Ciaudo, Ana Marques of “The Messenger”! contribution. Making things even better, the and Raffaella Santoro) have put together a University of Bern thereupon decided to also great program with an amazing list of teach- increase their contribution by 7.5%. Our ers. When looking at the program, I wish I network had grown so much during the first could be a PhD student again. phase that we were preparing for substantial A topic that we have discussed on several financial cuts on many of our activities (as occasions in the past was that we should try outlined in our full proposal for phase 2), but to improve our efforts in developing our re- thanks to the unexpected additional money, search findings towards medical applications the extent of these cuts will now be more or into products that have the potential for moderate and essentially all planned projects commercialization. In order to incentivize can be implemented. all our members and associate members to Another positive consequence of the im- propose and develop such projects, we made proved funding situation is that we could two calls for postdoctoral fellowships (con- integrate into our NCCR as a full member sult the KTT section of the NCCR’s website), Jacob Corn, the new professor of genome one of them requiring a collaboration with Oliver Mühlemann signs the contract for biology at the ETH (since Oct 2018) and an clinicians at the Inselspital Bern, and the Phase 2 of the NCCR RNA & Disease. THE NCCR RNA & DISEASE MESSENGER, No. 11, July 2019 2 Interview with Matthias Hentze “ The field as such was not looking for such types of RNA-binding proteins.” Interview: Dominik Theler In this interview Matthias Hentze of decades ago. In China, I see a lot of appe- research besides the endurance that both of gives his perspective on pursuing tite to tackle things and to progress. Unless them require? an academic career and tells us about we somehow find a way to address that, we Patience. I would certainly not be able to the discovery of “non-canonical” RNA will fall behind. finish a marathon without it. You come to binding proteins and the “Riboregula- I do not know how it is here, but at in- points where you wish it is over soon, and if tion” concept. stitutions like EMBL, that should be exem- you still have 15 kilometers to go, you have plary, that provide an amazing infrastructure this urge to accelerate and get it done and and people with a key to work anytime 24/7 over with quickly. If you do this with 15 kilo- Where do you see the European research when they choose to, you are a bit surprised meters still ahead of you, you are not going landscape standing, also in comparison to by how few people you meet if you enter to make it to the finish line. There is a lot of China and the USA? labs on a Friday afternoon after five. this in science as well: you need the right There are many challenges. Europe is current- patience and strategy to make it along a long ly struggling more than maybe it was a few distance. years ago. I hope it finds out of that phase. I think the comradery and then the col- Regarding research, there are potential syn- legiality in sports is also very fitting to sci- ergies that we should make use of but are “ I know, times have ence. I have been in marathon races where not. In a lot of places in Europe, there is fan- changed and this somebody was pushed in a wheelchair and tastic science going on, so on a small scale runners were taking turns to push the wheel- it is working well, but we are not obtaining a was a very lucky strike.” chair forward. I think this is wonderful at the commensurate more structured and strategic hobby runners’ level and also when it hap- benefit at the national or even continental pens in science: being ambitious for yourself level. but not against but together with others is a US research, I think, is currently going Being a researcher at EMBL provides you the fantastic parallel not just between marathon through a crisis. I hope it will recover soon, environment and resources to put it in soccer running and science, but sports and science. and I do not have any pleasure from a com- terms to play at the Champions League level petitive viewpoint that now, by comparison, research-wise, but doing so still requires per- How did you become a basic scientist after we are doing better because they have prob- sonal commitment. studying medicine? lems. I think the opposite is the case: The That is right: it requires personal commitment I started medical school because I wanted to better the science in the US, the more excit- and also dedication. You do not play Cham- treat patients, I finished medical school and I ing it is for European scientists to be part of pions League in soccer or Grand Slam finals still wanted to treat patients. I then wanted that global community. in tennis if you are not passionate about it to combine it with science becoming a physi- Both for US and for European research at every given moment, even on a Saturday cian-scientist in the area of gastroenterology the way that science is tackled these days in or on a Sunday. That sounds very old fash- and hepatology. I felt well prepared for the Asia, you specifically mentioned China, poses ioned, I know. I realize that not being in the a challenge. I think we have become in many lab does not mean that you are not working parts of the west a bit complacent about our on your research, particularly now that data work habits. They have become a little less analysis has become a much larger part of “ I think we should not driven than at least I felt they were a couple experimental progress. There is a lot of data analysis that one can do in the comfort of only be judging out- home rather than in a lab where you have centrifuges running in the background.
Load more

Recommended publications
  • NEWSLETTER – March 2016
    BRITISH SOCIETY FOR PROTEOME RESEARCH www.bspr.org UK Charity Number 1121692 Registered Company No.6319769 NEWSLETTER – March 2016 BSPR 2016 – PROTEOMIC APPROACHES TO HEALTH AND DISEASE University of Glasgow – 25-27 July 2016 th th The 2016 meeting of the Society will be held in the Western Infirmary Lecture Theatre building from Mon 25 – Wed 27 July 2016. For up to date information: (www.bspr.org/node/527) Abstract submission now open. Deadline: Mon 6th May. Registration opening shortly! Speakers include: Plenary - Matthias Mann – Max-Planck Institute for Biochemistry, Martinsried (GER) Rob Beynon (BSPR Lecturer 2016) – University of Liverpool (UK) Keynote: -Cancer: Judit Villen – University of Washington, Genome Sciences (US) Integration Omics: David Matthews – University of Bristol (UK) Metabolic disease: Harald Mischak – University of Glasgow (UK) Development and ageing: Xavier Druart - French Nat’l Inst for Agricultural Res, Nouzilly (FR) Nutrition/Lifestyle & Food Security: David Eckersall - University of Glasgow (UK) Infectious disease and Microbiome: Frank Schmidt – University of Greifswald (GER) New Technologies - Matthias Hentze – EMBL Heidelberg (GER) Data Analysis – Maria Martin – EMBL-EBI Cambridge (UK) Translation – Chris Sander, New York (US) More than 20 abstracts will be selected for oral presentation! Bursaries and Awards BSPR 2016 - The Society will be awarding the MJ Dunn Fellowship for attendance at BSPR 2016, and will also be awarding Bursaries to student members (£250) to enable them to attend a conference of their choice, including BSPR 2016. 10th European Summer School EMBO Workshop “Advanced Proteomics”, July 31st – August 6th, 2016. The Society will be awarding one or two bursaries (residential registration fee) to student members to enable them attend this workshop which will be held in Kloster Neustift, Brixen/Bressanone, South Tyrol, Italy.
    [Show full text]
  • The Helicase Ded1p Controls Use of Near-Cognate Translation Initiation Codons in 5Utrs
    The helicase Ded1p controls use of near- cognate translation initiation codons in 5# UTRs The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Guenther, Ulf-Peter et al. "The helicase Ded1p controls use of near- cognate translation initiation codons in 5# UTRs." Nature 559, 7712 (June 2018): 130–134. © 2018 Macmillan Publishers Ltd., part of Springer Nature As Published http://dx.doi.org/10.1038/s41586-018-0258-0 Publisher Springer Science and Business Media LLC Version Author's final manuscript Citable link https://hdl.handle.net/1721.1/125996 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2018 December 27. Published in final edited form as: Nature. 2018 July ; 559(7712): 130–134. doi:10.1038/s41586-018-0258-0. The helicase Ded1p controls use of near-cognate translation initiation codons in 5′UTRs Ulf-Peter Guenther1,*, David E. Weinberg2,3,*, Meghan M. Zubradt2,4,*, Frank A. Tedeschi1, Brittany N. Stawicki1, Leah L. Zagore1, Gloria A. Brar5, Donny D. Licatalosi1, David P. Bartel3, Jonathan S. Weissman2,4, and Eckhard Jankowsky1,6,7 1Center for RNA Science and Therapeutics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA 2Department of Cellular and Molecular Pharmacology, University of California,
    [Show full text]
  • Future Plans from the New Head of Personnel What's It Really Like to Come to EMBL As a Predoc? Official: Nordic EMBL Partnersh
    41 EMBL October 2007 &Newslettercetera of the European Molecular Biology Laboratory What’s it really like to come to EMBL as a predoc? A predoc’s first few weeks at EMBL can be a culture shock. It often means coping with a new language, finding a new home, meeting so many people that you can’t remember any names and, more often than not, leaving friends behind. But it’s also the beginning of a brilliant opportunity. Inside, Mateusz Putyrski, a new PhD in Carsten Schultz’s lab at EMBL Heidelberg in August, talks about how to settle in smoothly – and once settled in, how to stay connected to the outside world. page 5 Future plans from the new Head of Personnel One of Yann Chabod’s first tasks as Head of the Personnel department will be to oversee the imple- mentation of its new SAP HR database early next year, replacing the old PAISY system, which will be, as he says, “a big, big change in the way we do everything. The day-to-day job is being done well already. We’ve got very good people here but we can still improve the quality of our customer service with the right tools. I’m here to help and support them... and to learn about this new field!” page 3 Official: Nordic EMBL Partnership for Molecular Medicine University rectors and ministry and council representatives from Scandinavia came to EMBL Heidelberg on October 3 for the official agreement signing of the Nordic EMBL Partnership for Molecular Medicine. The partnership will combine the recognised, complementary strengths of all four partners to collaborate closely in the area of molecular medicine, tackling some of the most challeng- ing problems in biomedicine.
    [Show full text]
  • Program Information
    RNA 2021 The 26th Annual Meeting of the RNA Society On-line May 25–June 4, 2021 RNA 2021 On-Line The 26th Annual Meeting of the RNA Society CORRECT THE MESSAGE CHANGE A LIFETM Locanabio’s CORRECTXTM platform is pioneering a new class of gene therapies by correcting the th th May 25 – June 4 , 2021 dysfunctional RNA that causes a broad range of neurodegenerative, neuromuscular and retinal diseases Gene Yeo – University of California San Diego, USA Katrin Karbstein – Scripps Research Institute, Florida, USA V. Narry Kim – Seoul National University, South Korea Anna Marie Pyle – Yale University, USA Xavier Roca – Nanyang Technological University, Singapore Jörg Vogel – University of Würzburg, Germany RNA 2021 • On-line GENERAL INFORMATION Citation of abstracts presented during RNA 2021 On-line (in bibliographies or other) is strictly prohibited. Material should be treated as personal communication and is to be cited only with the expressed written ® consent of the author(s). The Sequel IIe System NO UNAUTHORIZED PHOTOGRAPHY OF ANY MATTER PRESENTED DURING THE ON-LINE MEETING: To encourage sharing of unpublished data at the RNA Society Annual Meeting, taking of photographs, screenshots, videos, and/or downloading or saving Reveal the functional e ects any material is strictly prohibited. of alternative splicing with USE OF SOCIAL MEDIA: The official hash tag of the 26th Annual Meeting of the RNA Society is full-length transcript sequencing #RNA2021. The organizers encourage attendees to tweet about the amazing science they experience during the meeting. However, please respect these few simple rules when using the #RNA2021 hash tag, or when talking about the meeting on Twitter and other social media platforms: 1.
    [Show full text]
  • The Cell's 'New World': First Complete Atlas of RNA-Binding Proteins 1 June 2012
    The cell's 'New World': First complete atlas of RNA-binding proteins 1 June 2012 In one of the most famous faux pas of exploration, will enable scientists to study how the cell's Columbus set sail for India and instead machinery adapts to stressful situations, responds 'discovered' America. Similarly, when scientists at to drugs or to changes in metabolism, or is altered the European Molecular Biology Laboratory in disease. (EMBL) in Heidelberg, Germany, set out to find enzymes - the proteins that carry out chemical reactions inside cells - that bind to RNA, they too Provided by European Molecular Biology found more than they expected: 300 proteins Laboratory previously unknown to bind to RNA - more than half as many as were already known to do so. The study, published online today in Cell, could help to explain the role of genes that have been linked to diseases like diabetes and glaucoma. "We are very excited that, unlike Columbus, we found what we were looking for: well-known enzymes that bind to RNA," says Matthias Hentze, who led the study at EMBL with Jeroen Krijgsveld. "But we never thought there was still so much unexplored territory, so many of these RNA- binding proteins to be discovered." Almost 50 of the new proteins Hentze and Krijgsveld found are encoded by genes known to be mutated in patients suffering from a variety of diseases, from diabetes and glaucoma to prostate and pancreatic cancers. This finding opens new avenues for researchers studying these disorders. It raises the possibility that such conditions could be caused by a malfunction not in the protein's previously established function, but in its potential role in RNA control.
    [Show full text]
  • Curriculum Vitae Professor Dr. Matthias W. Hentze
    Curriculum Vitae Professor Dr. Matthias W. Hentze Name: Matthias W. Hentze (Prof. Dr. med., Dr. h. c.) Born: 25 January 1960 Image: EMBL Photolab Massimo del Pete Research Priorities: Control of protein synthesis, Post-transcriptional control of gene regulation and its disorders in genetic diseases, Regulation of human iron metabolism, Metabolic processes and gene regulation, Riboregulation Matthias Hentze is a physician. For many years, his research focused on the understanding of posttranscriptional gene regulation, especially the control of protein synthesis. His work has also provided fundamental insights into the molecular mechanisms governing iron homeostasis and diseases of altered iron metabolism. At present, Hentze investigates connections between gene regulation and metabolism. Following their discovery of hundreds of new RNA-binding proteins, his team investigates the process of riboregulation, a novel biological control mechanism that they also recently described. Academic and Professional Career since 2013 Director, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany since 2005 Associate Director, European Molecular Biology Laboratory (EMBL) since 2005 Professor (apl.), Medical Faculty, University of Heidelberg (Ruprecht-Karls- Universität), Germany since 2002 Co-Director “Molecular Medicine Partnership Unit”, University of Heidelberg / EMBL 2001 - 2005 Unit Coordinator “Training, Partnership & Endowment”, EMBL since 1998 Senior Scientist, EMBL 1996 - 2005 Dean of Graduate Studies, EMBL Nationale Akademie der Wissenschaften Leopoldina www.leopoldina.org 1 1990 Habilitation in “Medical Molecular Biology”, Faculty for Theoretical Medicine, University of Heidelberg, Hermany since 1989 Group Leader, EMBL 1987 - 1989 Visiting Associate, National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA 1985 - 1987 Guest Researcher, National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892, USA 1985 Attending Physician, Internal Medicine, St.
    [Show full text]
  • EMBC Annual Report 2008
    EMBO | EMBC annual report 2008 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION | EUROPEAN MOLECULAR BIOLOGY CONFERENCE EMBO | EMBC table of contents introduction preface by Hermann Bujard, EMBO 5 preface by Tim Hunt, EMBO Council 8 preface by Peter Weisbeek & Krešimir Pavelić, EMBC 9 past & present timeline & brief history 12 EMBO | EMBC | EMBL aims 14 EMBO actions 2008 17 EMBC actions 2008 21 EMBO & EMBC programmes and activities fellowship programme 24 courses & workshops programme 25 young investigator programme 26 installation grants 27 science & society programme 28 EMBO activities The EMBO Journal 32 EMBO reports 33 Molecular Systems Biology 34 EMBO Molecular Medicine 35 journal subject categories 36 national science reviews 37 The EMBO Meeting 38 women in science 39 gold medal 40 award for communication in the life sciences 41 plenary lectures 42 information support & resources 43 public relations & communications 44 European Life Sciences Forum (ELSF) 45 ➔ 2 table of contents appendix EMBC delegates and advisers 48 EMBC scale of contributions 55 EMBO council members 2008 56 EMBO committee members & auditors 2008 57 EMBO council members 2009 58 EMBO committee members & auditors 2009 59 EMBO members elected in 2008 60 advisory editorial boards & senior editors 2008 72 long-term fellowship awards 2008 76 long-term fellowships: statistics 94 long-term fellowships 2008: geographical distribution 96 short-term fellowship awards 2008 98 short-term fellowships: statistics 116 short-term fellowships 2008: geographical distribution 118 young investigators
    [Show full text]
  • EMBO Facts & Figures
    excellence in life sciences young investigators|courses,workshops,conference series & symposia|installation grantees|long-term fellows|short-term fellows|policy, science & society|the EMBO Journal|EMBO reports|molecular systems biology|EMBO molecular medicine|global exchange|gold medal|the EMBO meeting|women in science| EMBO reports|molecular systems biology|EMBO molecular medicine|global exchange|gold medal|the EMBO meeting|women in science|young investigators|courses,workshops,conference series & symposia|installation grantees|long-term fellows|short-term fellows|policy, science & society|the EMBO Journal| global exchange|gold medal|the EMBO meeting|women in science|young investigators|long-term fellows|short-term fellows|policy, science & society|the EMBO Journal|courses,workshops,conference series & symposia|EMBO reports|molecular systems biology|EMBO molecular medicine|installation grantees| EMBO molecular medicine|installation grantees|long-term fellows|gold medal|molecular systems biology|short-term fellows|the EMBO meeting|womenReykjavik in science|young investigators|courses,workshops,conference series & symposia|global exchange|EMBO reports|policy, science & society|the EMBO Journal| gold medal|the EMBO meeting|women in science|young investigators|courses,workshops,conference series & symposia|global exchange|policy, science & society|the EMBO Journal|EMBO reports|molecular systems biology|EMBO molecular medicine|installation grantees|long-term fellows|short-term fellows| courses,workshops,conference series & symposia|global
    [Show full text]
  • Research at a Glance 2011
    European Molecular Biology Laboratory Research at a Glance 2011 European Molecular Biology Laboratory Research at a Glance 2011 Research at a Glance 2011 Contents 4 Foreword by Iain Mattaj, EMBL Director General 5 EMBL Heidelberg, Germany 6 Cell Biology and Biophysics Unit 17 Developmental Biology Unit 26 Genome Biology Unit 35 Structural and Computational Biology Unit 48 Directors’ Research 52 Core Facilities 61 EMBL-EBI, Hinxton, UK European Bioinformatics Institute 89 EMBL Grenoble, France Structural Biology 100 EMBL Hamburg, Germany Structural Biology 109 EMBL Monterotondo, Italy Mouse Biology 116 Index Foreword by EMBL‘s Director General EMBL – Europe’s leading laboratory for basic research in molecular biology The vision of the nations which founded the European Molecular Biology Laboratory was to create a centre of excellence where Europe’s best brains would come together to conduct basic research in molecular biology. During the past three decades, EMBL has grown and developed substantially, and its member states now number twenty-one, including the first associate member state, Australia. Over the years, EMBL has become the flagship of European molecular biology and has been continuously ranked as one of the top research institutes worldwide. EMBL is Europe’s only intergovernmental laboratory in the life sciences and as such its missions extend be- yond performing cutting-edge research in molecular biology. It also offers services to European scientists, most notably in the areas of bioinformatics and structural biology, provides advanced training to researchers at all levels, develops new technologies and instrumentation and actively engages in technology transfer for the ben- efit of scientists and society.
    [Show full text]
  • MOSBACHER Kolloquium PROGRAM
    GBM 66. Mosbacher Kolloquium Metals in Biology - Cellular Functions and Diseases March 26 - 28, 2015 preliminary Program Organization Scientific Organizers: Martina Muckenthaler Ruprecht Karls University Heidelberg, Germany Roland Lill Philipps University Marburg, Germany Ralf-R. Mendel Technische Universität Braunschweig, Germany Conference Office: Sabine Hähnke-Metzen Anke Lischeid Tino Apel German Society for Biochemistry and Molecular Biology (GBM) Mörfelder Landstr. 125 60598 Frankfurt am Main Germany Tel +49 69 660567 0 Fax + 49 69 660567 22 [email protected] www.gbm-online.de Like it on Facebook 2 Table of Contents Organization 2 Welcome address 4 Program at a glance 5 Program 9 Prize lectures 14 Students for students 16 Social program 17 General remarks Accommodation 18 Conference office 18 Internet access 18 Lunch & coffee breaks 19 Posters 19 Industrial exhibition 19 Registration 20 Proceedings 21 Venue 21 Exhibitors 22 Sponsors 23 3 Welcome Address Dear Colleagues, The traditional spring meetings of the German Society for Biochemistry and Molecular Biology (GBM) are held annually in the picturesque town of Mosbach to promote the exchange of scientific ideas and to foster the educa- tion of young scientists. The scientific theme of the 66th meeting is “Metals in Biology: Cellular functions and diseases”. Metals such as iron, copper, molybdenum, mangane- se and zinc participate in many biochemical and cell biological processes. More than 40% of the cellular proteins bind a functionally critical metal or metal-co- factor. Hence, acquisition, intracellular distribution, and protein insertion of metals are essential for cell viability. Conversely, unbound metals are toxic, thus requiring sophisticated regulatory systems to assure adequate cellular uptake, storage and export.
    [Show full text]
  • EMBC Annual Report 2005
    EMBO | EMBC annual report 2005 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION | EUROPEAN MOLECULAR BIOLOGY CONFERENCE EMBO | EMBC table of contents introduction preface by Frank Gannon, EMBO 4 preface by Susan Gasser, EMBO Council 6 preface by Marja Makarow, EMBC 8 past & present timeline 12 brief history 13 EMBO | EMBC | EMBL 14 EMBO actions 2005 17 EMBC actions 2005 19 EMBO & EMBC programmes and activities fellowship programme 23 courses & workshops programme 24 world activities 25 young investigator programme 26 women in the life sciences 27 science & society programme 28 electronic information programme 29 EMBO activities The EMBO Journal 32 EMBO reports 33 Molecular Systems Biology 34 journal subject categories 35 national science reviews 36 gold medal 37 award for communication in the life sciences 38 sectoral meetings 39 plenary lectures 40 communications offi ce 41 European Life Sciences Forum (ELSF) 42 ➔ 2 table of contents appendix EMBC delegates and advisers 46 EMBC scale of contributions 53 EMBO council members 2005 54 EMBO committee members & auditors 2005 55 EMBO council members 2006 56 EMBO committee members & auditors 2006 57 EMBO members elected in 2005 58 advisory editorial boards & senior editors 2005 66 long-term fellowship awards 2005 70 long-term fellowships: statistics 84 long-term fellowships 2005: geographical distribution 86 short-term fellowship awards 2005 88 short-term fellowships: statistics 102 short-term fellowships 2005: geographical distribution 104 young investigators 2005 106 young investigators 2000 – 2004 107 young investigators: statistics 108 young investigator lectures 2005 110 courses | workshops | conferences | symposia 2005 112 plenary lectures 2005 118 participation of women in EMBO activities: statistics 120 EMBO staff 124 events in 2006 courses | workshops | conferences | conference series | symposia 2006 128 plenary lectures 2006 134 other EMBO events 2006 136 organisations and acronyms 138 ➔ 3 preface EMBO & EMBC 2005 An awkward time warp surrounds annual 1200 applications for long-term fellowships and reports.
    [Show full text]
  • Press Release
    Press Release The cell’s ‘New World’ First complete atlas of RNA-binding proteins could point to function of genes linked to diseases Heidelberg, 31 May 2012 – In one of the most famous faux pas of exploration, Columbus set sail for India and instead ‘discovered’ America. Similarly, when scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, set out to find enzymes – the proteins that carry out chemical reactions inside cells – that bind to RNA, they too found more than they expected: 300 proteins previously unknown to bind to RNA – more than half as many as were already known to do so. The study, published online today in Cell, could help to explain the role of genes that have been linked to diseases like diabetes and glaucoma. “We are very excited that, unlike Columbus, we found what we were looking for: well-known enzymes that bind to RNA,” says Matthias Hentze, who led the study at EMBL with Jeroen Krijgsveld. “But we never thought there was still so much unexplored territory, so many of these RNA-binding proteins Scientists catalogued all proteins that bind to RNA, finding 300 previously to be discovered.” unknown to do so. Almost 50 of the new proteins Hentze and Krijgsveld found are encoded by genes known to be mutated in patients suffering isolating all proteins that bind to RNA in living cells. The new from a variety of diseases, from diabetes and glaucoma to approach will have many further uses, as it can be applied prostate and pancreatic cancers. This finding opens new avenues to other cell types and conditions, to explore which proteins for researchers studying these disorders.
    [Show full text]